Viruses and the 26S proteasome: Hacking into destruction

Trends in Biochemical Sciences

Volumn 28, Issue 8, 2003, Pages 452-459

  Banks, Lawrence ^a   Pim, David ^a   Thomas, Miranda ^a  

^a INTERNATIONAL CENTRE FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ONCOPROTEIN; PROTEASOME; PROTEIN KINASE; PROTEIN P53; UBIQUITIN PROTEIN LIGASE; VIRUS ENZYME; VIRUS PROTEIN;

CELL CYCLE; CELL FUNCTION; CELL SURVIVAL; ENZYME ANALYSIS; ENZYME STRUCTURE; ENZYME SUBSTRATE; LIFE CYCLE; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN TARGETING; REVIEW; STRUCTURE ANALYSIS; VIRUS CARCINOGENESIS; VIRUS CELL INTERACTION; VIRUS REPLICATION; WART VIRUS;

HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPES; PAPILLOMAVIRUS;

EID: 0042157103     PISSN: 09680004     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0968-0004(03)00141-5     Document Type: Review

References (79)

1. Coscoy L., et al. A novel class of herpesvirus-encoded membrane-bound E3 ubiquitin ligases regulates endocytosis of proteins involved in immune recognition. J. Cell Biol. 155:2001;1265-1273.
2. Harty R.N., et al. Rhabdoviruses and the cellular ubiquitin-proteasome system: a budding interaction. J. Virol. 75:2001;10623-10629.
3. Winberg G., et al. Latent membrane protein 2A of Epstein-Barr virus binds WW domain E3 protein-ubiquitin ligases that ubiquitinate B-cell tyrosine kinases. Mol. Cell. Biol. 20:2000;8526-8535.
4. Galinier R., et al. Adenovirus protein involved in virus internalisation recruits ubiquitin-protein ligases. Biochemistry. 41:2002;14299-14305.
5. Beachy R.N., Heinlein M. Role of P30 in replication and spread of TMV. Traffic. 1:2000;540-544.
6. Petersen H., et al. Transferring substrates to the 26S proteasome. Trends Biochem. Sci. 28:2003;26-31.
7. Maul G.G. Nuclear domain 10, the site of DNA virus transcription and replication. Bioessays. 20:1998;660-667.
8. Maul G.G., et al. Nuclear domain 10 as pre-existing potential replication start sites of herpes simplex virus type 1. Virology. 217:1996;67-75.
9. Everett R.D., et al. The disruption of ND10 during herpes simplex virus infection correlates with the Vmw110- and proteasome-dependent loss of several PML isoforms. J. Virol. 72:1998;6581-6591.
10. Chelbi-Alix M.K., de The H. Herpes virus induced proteasome-dependent degradation of the nuclear bodies-associated PML and Sp100 proteins. Oncogene. 18:1999;935-941.
11. Everett R.D. ICP0, a regulator of herpes simplex virus during lytic and latent infection. Bioessays. 22:2000;761-770.
12. Joazeiro C.A., Weissman A.M. RING finger proteins: mediators of ubiquitin ligase activity. Cell. 102:2000;549-552.
13. Boutell C., et al. Herpes simplex virus type 1 immediate-early protein ICP0 and its isolated RING finger domain act as ubiquitin E3 ligases in vitro. J. Virol. 76:2002;841-850.
14. Nuber U., et al. Cloning of human Ub-conjugating enzymes UbcH6 and UbcH7 (E2-F1) and characterisation of their interaction with E6-AP and RSP5. J. Biol. Chem. 271:1996;2795-2800.
15. Parkinson J., et al. Herpes simplex virus type 1 immediate-early protein Vmw110 induces the proteasome-dependent degradation of the catalytic subunit of DNA-dependent protein kinase. J. Virol. 73:1999;650-657.
16. Everett R.D., et al. Specific destruction of kinetochore protein CENP-C and disruption of cell division by herpes simplex virus immediate-early protein Vmw110. EMBO J. 18:1999;1526-1538.
17. Lomonte P., et al. Degradation of nucleosome-associated centromeric histone H3-like protein CENP-A induced by herpes simplex virus type 1 protein ICP0. J. Biol. Chem. 276:2001;5829-5835.
18. Everett R.D., et al. The ability of Herpes simplex virus type 1 immediate-early protein Vmw110 to bind to a ubiquitin-specific protease contributes to its roles in the activation of gene expression and stimulation of virus replication. J. Virol. 73:1999;417-426.
19. Everett R.D., et al. A novel ubiquitin-specific protease is dynamically associated with the PML nuclear domain and binds to a herpesvirus regulatory protein. EMBO J. 16:1997;566-577.
20. Li M., et al. De-ubiquitination of p53 by HAUSP is an important pathway for p53 stabilisation. Nature. 416:2002;648-653.
21. Van Sant C., et al. Role of Cyclin D3 in the biology of Herpes simplex virus 1 ICP0. J. Virol. 75:2001;1888-1898.
22. Nicholas J., et al. Herpesvirus saimiri encodes homologues of G protein-coupled receptor and cyclins. Nature. 355:1992;362-365.
23. Chang Y., et al. Cyclin encoded by KS herpesvirus. Nature. 382:1996;410.
24. Van Sant C., et al. The infected cell protein 0 of herpes simplex virus 1 dynamically interacts with proteasomes, binds and activates the cdc34 E2 ubiquitin conjugating enzyme, and possesses in vitro E3 ubiquitin ligase activity. Proc. Natl. Acad. Sci. U. S. A. 98:2001;8815-8820.
25. Yu Z.K., et al. Human CUL-1 associates with the SKP1/SKP2 complex and regulates p21 (CIP1/WAF1) and cyclin D proteins. Proc. Natl. Acad. Sci. U. S. A. 95:1998;11324-11329.
26. Maul G.G., Everett R.D. The nuclear location of PML, a cellular member of the C3HC4 zinc-binding domain protein family, is rearranged during herpes simplex virus infection by the C3HC4 protein ICP0. J. Gen. Virol. 75:1994;1223-1233.
27. Yew P.R., Berk A.J. Inhibition of p53 transactivation required for transformation by adenovirus early 1B protein. Nature. 357:1992;82-85.
28. Moore M., et al. Oncogenic potential of the adenovirus E4orf6 protein. Proc. Natl. Acad. Sci. U. S. A. 93:1996;11295-11301.
29. Sarnow P., et al. Adenovirus E1B 58 kD tumor antigen and SV40 large tumour antigen are physically associated with the same 54 kD cellular protein in transformed cells. Cell. 28:1982;387-394.
30. Dobner T., et al. Blockage by adenovirus E4orf6 of transcriptional activation by the p53 tumor suppressor. Science. 272:1996;1470-1473.
31. Kao C.C., et al. Domains required for in vitro association between the cellular p53 and the adenovirus 2 E1B 55K proteins. Virology. 179:1990;806-814.
32. Steegenga W.T., et al. The large E1B protein together with the E4orf6 protein target p53 for active degradation in adenovirus infected cells. Oncogene. 16:1998;349-357.
33. Boivin D., et al. Analysis of synthesis, stability, phosphorylation, and interacting polypeptides of the 34-kilodalton product of open reading frame 6 of the early region 4 protein of human adenovirus type 5. J. Virol. 73:1999;1245-1253.
34. Querido E., et al. degradation of p53 by adenovirus E4orf6 and E1B55k proteins occurs via a novel mechanism involving a Cullin-containing complex. Genes Dev. 15:2001;3104-3117.
35. Harada J.N., et al. Analysis of the adenovirus E1B-55k-anchored proteome reveals its link to ubiquitination machinery. J. Virol. 76:2002;9194-9206.
36. Lisztwan J., et al. The von Hippel-Lindau tumour suppressor protein is a component of an E3 ubiquitin-protein ligase activity. Genes Dev. 13:1999;1822-1833.
37. Kamura T., et al. Activation of HIF1α ubiquitination by a reconstituted von Hippel-Lindau (VHL) tumour suppressor complex. Proc. Natl. Acad. Sci. U. S. A. 97:2000;10430-10435.
38. Patton E.E., et al. Combinatorial control in ubiquitin-dependent proteolysis: Don't skp the F-box hypothesis. Trends Genet. 14:1998;236-243.
39. Ohh M., et al. An intact NEDD8 pathway is required for Cullin-dependent ubiquitylation in mammalian cells. EMBO Rep. 3:2002;177-182.
40. Thomas M., et al. The role of the E6-p53 interaction in the molecular pathogenesis of the HPV. Oncogene. 18:1999;7690-7700.
41. Clayton-Smith J., Laan L. Angelman syndrome: a review of the clinical and genetic aspects. J. Med. Genet. 40:2003;87-95.
42. Scheffner M., et al. Protein ubiquitination involving an E1-E2-E3 enzyme ubiquitin thioester cascade. Nature. 373:1995;81-83.
43. Huibregtse J.M., et al. A family of proteins structurally and functionally related to the E6-AP ubiquitin-protein ligase. Proc. Natl. Acad. Sci. U. S. A. 92:1995;2563-2567.
44. Huang L., et al. Structure of an E6AP-UbcH7 complex: insights into ubiquitination by the E2-E3 enzyme cascade. Science. 286:1999;1321-1326.
45. Kumar S., et al. Physical interaction between specific E2 and Hect E3 enzymes determines functional cooperativity. J. Biol. Chem. 272:1997;13548-13554.
46. Elston R.C., et al. The identification of a conserved binding motif within human papillomavirus type 16 E6 binding peptides, E6AP and E6BP. J. Gen. Virol. 79:1998;371-374.
47. Beer-Romero P., et al. Antisense targeting of E6-AP elevates p53 in HPV-infected cells but not in normal cells. Oncogene. 14:1997;595-602.
48. Talis A.L., et al. The role of E6AP in the regulation of p53 protein levels in human papillomavirus (HPV)-positive and HPV-negative cells. J. Biol. Chem. 273:1998;6439-6445.
49. Butz K., et al. Induction of apoptosis in human papillomavirus-positive cancer cells by peptide aptamers targeting the viral E6 oncoprotein. Proc. Natl. Acad. Sci. U. S. A. 97:2000;6693-6697.
50. Honda R., et al. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumour suppressor p53. FEBS Lett. 420:1997;25-27.
51. Hengstermann A., et al. Complete switch from Mdm2 to human papillomavirus E6-mediated degradation of p53 in cervical cancer cells. Proc. Natl. Acad. Sci. U. S. A. 98:2001;1218-1223.
52. Bech-Otschir D., et al. COP9 signalosome-specific phosphorylation targets p53 to degradation by the ubiquitin system. EMBO J. 20:2001;1630-1639.
53. Kao W.H., et al. Human papillomavirus type 16 E6 induces self-ubiquitination of the E6-AP ubiquitin protein ligase. J. Virol. 74:2000;6408-6417.
54. Thomas M., Banks L. Inhibition of Bak-induced apoptosis by HPV-18 E6. Oncogene. 17:1998;2943-2954.
55. Gao Q., et al. Human papillomavirus E6-induced degradation of E6TP1 is mediated by E6AP ubiquitin ligase. Cancer Res. 62:2002;3315-3321.
56. Nakagawa S., Huibregtse J.M. Human scribble (Vartul) is targeted for ubiquitin-mediated degradation by the high-risk papillomavirus E6 proteins and the E6AP ubiquitin-protein ligase. Mol. Cell. Biol. 20:2000;8244-8253.
57. Srivenugopal K.S., Ali-Osman F. The DNA repair protein, O(6)-methylguanine-DNA methyltransferase is a proteolytic target for the E6 human papillomavirus oncoprotein. Oncogene. 21:2002;5940-5945.
58. Oda H., et al. Regulation of the Src family tyrosine kinase Blk through E6AP-mediated degradation. Proc. Natl. Acad. Sci. U. S. A. 96:1999;9557-9562.
59. Kumar S., et al. Identification of HHR23A as a substrate for E6-associated protein-mediated ubiquitination. J. Biol. Chem. 274:1999;18785-18792.
60. Pim D., et al. Mutational analysis of HPV-18 E6 identifies domains required for p53 degradation in vitro, abolition of p53 transactivation in vivo and immortalisation of primary BMK cells. Oncogene. 9:1994;1869-1876.
61. Nguyen M., et al. A mutant of human papillomavirus type 16 E6 deficient in binding α-helix partners displays reduced oncogenic potential in vivo. J. Virol. 76:2002;13039-13048.
62. Lee S.S., et al. Binding of human virus oncoproteins to hDlg/SAP97, a mammalian homolog of the Drosophila discs large tumor suppressor protein. Proc. Natl. Acad. Sci. U. S. A. 94:1997;6670-6675.
63. Gardiol D., et al. Oncogenic human papillomavirus E6 proteins target the discs large tumour suppressor for proteasome-mediated degradation. Oncogene. 18:1999;5487-5496.
64. Glaunsinger B., et al. Interactions of the PDZ-protein MAGI-1 with adenovirus E4-ORF1 and high-risk papillomavirus E6 oncoproteins. Oncogene. 19:2000;1093-1098.
65. Thomas M., et al. Oncogenic human papillomavirus E6 proteins target the MAGI-2 and MAGI-3 proteins for degradation. Oncogene. 21:2002;5088-5096.
66. Caruana G. Genetic studies define MAGUK proteins as regulators of epithelial cell polarity. Int. J. Dev. Biol. 46:2002;511-518.
67. Bilder D., et al. Cooperative regulation of cell polarity and growth by Drosophila tumor suppressors. Science. 289:2000;113-116.
68. Pim D., et al. HPV E6 targeted degradation of the discs large protein: evidence for the involvement of a novel ubiquitin ligase. Oncogene. 19:2000;719-725.
69. Pim D., et al. Chimaeric HPV E6 proteins allow dissection of the proteolytic pathways regulating different E6 cellular target proteins. Oncogene. 21:2002;8140-8148.
70. Münger K., et al. Biological activities and molecular targets of the human papillomavirus E7 oncoprotein. Oncogene. 20:2001;7888-7898.
71. Boyer S.N., et al. E7 protein of human papillomavirus-16 induces degradation of retinoblastoma protein through the ubiquitin-proteasome pathway. Cancer Res. 56:1996;4620-4624.
72. Berezutskaya E., Bagchi S. The human papillomavirus E7 oncoprotein functionally interacts with the S4 subunit of the 26S proteasome. J. Biol. Chem. 272:1997;30135-30140.
73. Luo H., et al. Ubiquitin-dependent proteolysis of Cyclin D1 is associated with coxsackievirus-induced cell growth arrest. J. Virol. 77:2003;1-9.
74. Kalejta R.F., et al. Human cytomegalovirus pp71 stimulates cell cycle progression by inducing the proteasome-dependent degradation of the retinoblastoma family of tumor suppressors. Mol. Cell. Biol. 23:2003;1885-1895.
75. van der Wal F.J., et al. The HCMV gene products US2 and US11 target MHC class I molecules for degradation in the cytosol. Curr. Top. Microbiol. Immunol. 269:2002;37-55.
76. Gotoh B., et al. Paramyxovirus strategies for evading the interferon response. Rev. Med. Virol. 12:2002;337-357.
77. Mansouri M., et al. The PHD/LAP-domain protein M153R of myxomavirus is a ubiquitin ligase that induces the rapid internalisation and lysosomal destruction of CD4. J. Virol. 77:2003;1427-1440.
78. Licata J.M., et al. Overlapping motifs (PTAP and PPEY) within the Ebola virus VP40 protein function independently as late budding domains: involvement of host proteins TSG101 and VPS-4. J. Virol. 77:2003;1812-1819.
79. Yasuda J., et al. Functional involvement of a novel Nedd4-like ubiquitin ligase on retrovirus budding. EMBO Rep. 3:2002;636-640.